CanBas is aiming to find a cure for cancer patients. Its lead oncology drug candidate is a unique calmodulin modulator CBP501 that increases platinum influx specifically into tumor cells. It showed promising sings of activities in platinum refractory/resistant ovarian cancer and malignant pleural mesothelioma populations in combination with platinum. CanBas identified additional unique MoA of CBP501 that are 1) induction of tumor immunogenic cell death, 2) suppression of M2 macrophages, 3) reduction of cancer stem cell population, and 4) suppression of migration, invasion and epithelial-to-mesenchymal transition of tumor cells. Given positive preclinical data, CanBas is running a Phase Ib study in the USA with CBP501+Cisplatin+Nivolumab triple drug combination. Expansion cohort on pancreatic and MSS colon cancer had started based on promising dose finding cohort results including a partial response in a heavily pretreated pancreatic cancer patient with other multiple long SDs.
Tokyo Stock Exchange Mothers
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):